Journal
JOURNAL OF PATHOLOGY
Volume 230, Issue 4, Pages 356-364Publisher
WILEY
DOI: 10.1002/path.4214
Keywords
intratumour heterogeneity; copy number; tumour evolution; chromosomal instability; biomarker; personalized medicine
Funding
- European Union Framework 7 programme PREDICT Consortium
- Villum Fonden
- Cancer Research UK
- Breast Cancer Research Foundation
- Prostate Cancer Foundation
- UK Medical Research Council
- NIHR RMH/ICR Biomedical Research Centre for Cancer
- MRC [G0902275] Funding Source: UKRI
- Medical Research Council [G0902275] Funding Source: researchfish
Ask authors/readers for more resources
Intratumour heterogeneity (ITH) may foster tumour adaptation and compromise the efficacy of personalized medicine approaches. The scale of heterogeneity within a tumour (intratumour heterogeneity) relative to genetic differences between tumours (intertumour heterogeneity) is unknown. To address this, we obtained 48 biopsies from eight stage III and IV clear cell renal cell carcinomas (ccRCCs) and used DNA copy-number analyses to compare biopsies from the same tumour with 440 single tumour biopsies from the Cancer Genome Atlas (TCGA). Unsupervised hierarchical clustering of TCGA and multi-region ccRCC samples revealed segregation of samples from the same tumour into unrelated clusters; 25% of multi-region samples appeared more similar to unrelated samples than to any other sample originating from the same tumour. We found that the majority of recurrent DNA copy number driver aberrations in single biopsies were not present ubiquitously in late-stage ccRCCs and were likely to represent subclonal events acquired during tumour progression. Such heterogeneous subclonal genetic alterations within individual tumours may impair the identification of robust ccRCC molecular subtypes classified by distinct copy number alterations and clinical outcomes. The co-existence of distinct subclonal copy number events in different regions of individual tumours reflects the diversification of individual ccRCCs through multiple evolutionary routes and may contribute to tumour sampling bias and impact upon tumour progression and clinical outcome. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available